| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 50.9 | 35.6 | 48.9 |
| Other income | 0.0 | 0.2 | 0.0 |
| Total income | 50.9 | 35.8 | 49.0 |
| Profit before exceptional items & tax | 14.4 | 10.6 | 15.5 |
| Profit before tax | 14.4 | 10.6 | 15.5 |
| Net profit | 11.1 | 5.2 | 16.6 |
| Operating margin | 28.3% | 29.6% | 31.6% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -33.10% |
|---|---|
| Net profit, quarter on quarter | +113.50% |
| Revenue, year on year | +4.10% |
NSE results filing, NSE: AHCL. Figures extracted from the filing.
Anlon Healthcare Ltd: key numbers
- Share price
- ₹31.51
- Market cap
- ₹167.5 Cr
- Revenue (annual)
- ₹172.0 Cr
- Net profit (annual)
- ₹28.51 Cr
- P/E (TTM)
- 5.3×Sector 50.4×
- Promoter holding
- 52.68%+0.00% QoQ
- FII holding
- 1.67%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Anlon Healthcare Ltd
All →Anlon Healthcare Merger & Restructuring
Anlon Healthcare incorporated ANLON Healthcare Nigeria Limited, holding 90% stake. The subsidiary aims to expand pharmaceutical and healthcare operations across 16 West African countries.
Anlon Healthcare Acquisition
Anlon Healthcare's AGM approved acquiring Apiqo Organics and Bizotic Lifescience stakes via share swap. The filing adds preferential issue pricing of ₹17.85 per share.
Anlon Healthcare Price Movement Clarification
Anlon Healthcare responded to NSE/BSE surveillance queries stating no undisclosed information explains the price movement. The company attributes the move to market-driven factors.
Anlon Healthcare Credit Rating
Brickwork Ratings assigned BWR BBB/Stable to Anlon Healthcare's ₹23.60 Crore fund-based term loan. The rating reflects improved profitability and low leverage following the company's 2025 IPO.
Anlon Healthcare Annual General Meeting
Anlon Healthcare Limited held its 13th Annual General Meeting on September 05, 2025. Shareholders considered financial statements, director appointments, and a preferential issue of equity shares.
Anlon Healthcare Investor Presentation: Key Takeaways
Anlon Healthcare Q1 FY27 results show strong top-line growth following the acquisition of Remember India Health Links, though EBITDA margins faced temporary pressure from surging raw material costs and consolidation expenses.
- Call
- Guides 30% growth